biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
PAb416, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
SV40-infected cells
manufacturer/tradename
Calbiochem®
storage condition
do not freeze
dilution
(Affinity Purification
Immunoblotting (1-5 µg/mL)
Immunofluorescence (1-5 µg/mL)
Immunoprecipitation (1-5 µg antibody)
Paraffin Sections )
isotype
IgG2a
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
General description
SV40 T Ag（Ab-2）是一种小鼠单克隆抗体，对SV40大T抗原特有的抗原决定簇具有特异性，与SV40小T抗原无反应性。两种抗原均由SV40基因组的早期区域编码。大的T抗原结合DNA，并与53,000道尔顿的细胞转化蛋白p53形成复合物，p53是裂解生长过程中启动病毒DNA复制所必需的。此外，大T抗原与DNA聚合酶和转录因子AP-2结合，并与视网膜母细胞瘤易感基因的p105产物形成特异性复合物。
识别SV80和SV-T2细胞中的~94 kDa SV40大T抗原。
该抗SV40 T抗原（Ab-2）小鼠mAb（PAb416）经验证可用于亲和纯化、免疫印迹、IF、IP和石蜡切片，以检测SV40 T抗原（Ab-2）。
通过用指定的免疫原免疫小鼠并将脾细胞与NS-1小鼠骨髓瘤融合而产生的纯化的小鼠单克隆抗体（请参阅应用参考）。识别~94 kDa SV40大T抗原。
Immunogen
纯化SV40大T抗原
表位：氨基酸83-128内
Application
亲和纯化（使用目录编号DP02A）
免疫印迹（1-5 µg/ml，请参阅应用参考）
免疫荧光（1-5 µg/ml）
免疫沉淀（1-5 µg抗体，使用目录编号DP02A）
石蜡切片（请参阅应用参考）
免疫印迹（1-5 µg/ml，请参阅应用参考）
免疫荧光（1-5 µg/ml）
免疫沉淀（1-5 µg抗体，使用目录编号DP02A）
石蜡切片（请参阅应用参考）
Packaging
请参考特定浓度批号的标签。
Physical form
溶于50 mM磷酸钠缓冲液（pH 7.5），含0.2％明胶。
Analysis Note
阳性对照
SV80或SV-T2细胞
SV80或SV-T2细胞
阴性对照
3T3细胞
3T3细胞
Other Notes
DeCaprio, J.A., et al. 1988.Cell54, 275.
Whyte, P., et al. 1988.Nature334, 124.
Mitchell, P.J., et al. 1987.Cell50, 847.
Dixon, R.A.F. and Nathans, D., 1985.J. Virol.53, 1001.
Simanis, V. and Lane, D.P.1985.Virol.144, 88.
Mann, R.S. and Carroll, R.B.1984.Virology138, 379.
Sarnow, P., et al. 1982.Cell28, 387.
Crawford, L.V., et al. 1981.Proc.Natl.Acad.Sci. USA78, 41.
Lane, D.P. and Crawford, L.V.1979.Nature278, 261.
Carroll, R.B., et al. 1974.Proc.Natl.Acad.Sci. USA71, 3754.
Tooze, J. 1973.Cold Spring Harbor, New York.
Tegtmeyer, P. 1972.J. Virol.10, 591.
Whyte, P., et al. 1988.Nature334, 124.
Mitchell, P.J., et al. 1987.Cell50, 847.
Dixon, R.A.F. and Nathans, D., 1985.J. Virol.53, 1001.
Simanis, V. and Lane, D.P.1985.Virol.144, 88.
Mann, R.S. and Carroll, R.B.1984.Virology138, 379.
Sarnow, P., et al. 1982.Cell28, 387.
Crawford, L.V., et al. 1981.Proc.Natl.Acad.Sci. USA78, 41.
Lane, D.P. and Crawford, L.V.1979.Nature278, 261.
Carroll, R.B., et al. 1974.Proc.Natl.Acad.Sci. USA71, 3754.
Tooze, J. 1973.Cold Spring Harbor, New York.
Tegtmeyer, P. 1972.J. Virol.10, 591.
也可用琼脂糖偶联物（目录编号DP02A），适用于亲和纯化和免疫沉淀。在单个系统中，应对抗体进行滴定以获得最佳结果。
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
毒性：标准处理（A）
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Archives of pathology & laboratory medicine, 142(9), e2-e202 (2018-09-13)
and case study poster sessions will be conducted during the 2018 College of American Pathologists Annual Meeting (CAP18), which is scheduled for October 20 to 24, 2018. The meeting will take place at the Hyatt Regency, Chicago, Illinois. The poster
Tobias May et al.
Methods in molecular medicine, 140, 1-15 (2007-12-19)
Cell therapies rely on the implantation of well-characterized functional cells with defined properties. Often, the cells of interest do not proliferate in vitro and thus cannot be expanded to the amount needed for characterization, purification, manipulation, or cloning. Here, we
B K Kleinschmidt-DeMasters et al.
Journal of neuropathology and experimental neurology, 71(7), 604-617 (2012-06-20)
The use of natalizumab to treat multiple sclerosis (MS) has been associated with the development of progressive multifocal leukoencephalopathy (PML), with 242 PML cases reported as of May 3, 2012. Fortunately, rapid withdrawal of the drug and administration of plasma
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| DP02-200UG | 07790788053734 |